Scholarlink

<p>We report the basal cell cancer (BCC) cohort of the SWOG/NCI 1609 <i>Dual</i> Anti-CTLA-4 &amp; Anti-PD-1 blockade in <i>Rare Tumors</i> (DART), a phase II prospective, multicenter basket trial of nivolumab and ipilimumab. The primary endpoint was objective response rate (ORR) (RECIST v1.1). Overall survival (OS), progression-free survival (PFS), and toxicity were secondary endpoints. Sixteen patients with advanced/metastatic BCC were evaluable. The ORR was 31% (95% CI, 19–50%), and the 12-month OS, 75% (95% CI, 57–100%). Median PFS was 9.3 months (95% CI, 3.3–NA). Of 15 patients evaluable for clinical benefit, five partial responses (PRs) and five stable disease &gt;6 months (total = 10/15 (66.7%)) were seen. The most common toxicities included fatigue (37.5%), pruritis (31.3%), and diarrhea (25%). In patients with advanced/metastatic BCC, ipilimumab and nivolumab produced an ORR of 31% and prolonged (&gt;6 months) PFS in 73% of patients, with seven PFS/iPFS of &gt;1 year, including one with prior anti-PD-1. ClinicalTrials.gov ID: NCT02834013 (Registered 7/15/2016; <a href="https://clinicaltrials.gov/ct2/show/NCT02834013">https://clinicaltrials.gov/ct2/show/NCT02834013</a>).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月24日

查看全文
  • Sandip P. Patel,
  • Eleanor Cano-Linson,
  • Young Kwang Chae,
  • Shiruyeh Schokrpur,
  • Christopher D. Lao,
  • Benjamin C. Powers,
  • Adrienne I. Victor,
  • Adedayo A. Onitilo,
  • Sarah Shin,
  • Naoko Takebe,
  • Sara Threlkel,
  • Christine M. McLeod,
  • Helen X. Chen,
  • Elad Sharon,
  • Megan Othus,
  • Christopher W. Ryan,
  • Charles D. Blanke,
  • Razelle Kurzrock

摘要

We report the basal cell cancer (BCC) cohort of the SWOG/NCI 1609 Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART), a phase II prospective, multicenter basket trial of nivolumab and ipilimumab. The primary endpoint was objective response rate (ORR) (RECIST v1.1). Overall survival (OS), progression-free survival (PFS), and toxicity were secondary endpoints. Sixteen patients with advanced/metastatic BCC were evaluable. The ORR was 31% (95% CI, 19–50%), and the 12-month OS, 75% (95% CI, 57–100%). Median PFS was 9.3 months (95% CI, 3.3–NA). Of 15 patients evaluable for clinical benefit, five partial responses (PRs) and five stable disease >6 months (total = 10/15 (66.7%)) were seen. The most common toxicities included fatigue (37.5%), pruritis (31.3%), and diarrhea (25%). In patients with advanced/metastatic BCC, ipilimumab and nivolumab produced an ORR of 31% and prolonged (>6 months) PFS in 73% of patients, with seven PFS/iPFS of >1 year, including one with prior anti-PD-1. ClinicalTrials.gov ID: NCT02834013 (Registered 7/15/2016; https://clinicaltrials.gov/ct2/show/NCT02834013).